Fasting Clinical Trial
Official title:
The Physical and Mental Effects of Prolonged Fasting With Meditation and Mild Physical Exercise
Verified date | October 2018 |
Source | Shanghai University of Traditional Chinese Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine the feasibility, safety and efficacy of fasting, participants are recruited in a 5-days fasting ( without any food, except unlimited mineral water),and do some fitness regimen (such as meditation and mild physical exercise ) during fasting.The samples will be collected from participates and subjected to comprehensive analysis ,including routine medical examination in blood, metabonomics and proteomics anlysis in serum and urine samples, gut microbiome analysis in stood samples, and so on.
Status | Active, not recruiting |
Enrollment | 45 |
Est. completion date | September 9, 2019 |
Est. primary completion date | April 9, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion criteria 1. 18-65 years old, no nationality limitation, no gender limitation; 2. Male weight = 50 kg, female weight = 45 kg;BMI: 19-28 kg/m²; 3. The index of physical examination is in line with health standards; 4. People who have gone through a 7-day fasting before ; 5. Agree to take part in the trials and sign the informed consent form. Exclusion criteria 1. People with unhealthy habits, such as smoking(5 cigarettes per day, or can not stop smoking in the trial), excessive drinking(drink regularly in the recent 6 months or more than 14 units of alcohol per week (1 unit = 360 ml beer or 45 ml alcohol with 40% spirits or 150 ml wine)) ; 2. People who processed fasting within one month; 3. Pregnancy, current breast-feeding or menstrual period; 4. People who are marantic, malnourished or anorectic; 5. People who have cardiovascular disease(coronary heart disease, atherosclerosis, arrhythmia, etc), serious metabolic and psychiatric disorders(hypertension, type 2 diabetes, hyperthyroidism, etc.); 6. People who have Mental illness, cancer, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), syphilis, human immunodeficiency virus (HIV) antibody positive. 7. people who has mental disorders according to the scales(Hamilton Anxiety Scale?Self-Rating Anxiety Scale?Self-rating depression scale) |
Country | Name | City | State |
---|---|---|---|
China | Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai University of Traditional Chinese Medicine |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Weight | Changes in weight will be assessed. | Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting | |
Primary | Blood glucose | Changes in blood glucose will be assessed. | Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting | |
Primary | Insulin | Changes in insulin will be assessed. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Primary | Blood pressure | Changes in blood pressure will be assessed. | Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting | |
Primary | Waistline | Changes in waistline will be assessed . | Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting | |
Primary | IGF-1 | Changes in IGF-1 will be assessed. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Primary | Pulse Rate | Changes in pulse rate will be assessed. | Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting | |
Primary | Blood lipid test | Changes in blood including HDL, LDL, TG, CHO and ect. will be assessed. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Primary | Urine test | Changes in urine including uric acid and ect. will be assessed. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Primary | Liver and renal function test | Changes in liver and renal function including AST,ALT,ALP, TP,ALB, Urea, Crea and ect will be assessed at 7:30 am. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Primary | Serum metabolomics analysis | Serum samples were collected and serum metabolomics (carbohydrate, lipid, amino acid and ect.) were sequenced and analyzed by High-throughput sequencing. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Secondary | Urinary ketone | Changes in urinary ketone will be assessed. | Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting | |
Secondary | Vitamin examination | Changes in vitamin including vitamin C,D,E and etc. will be assessed. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Secondary | Thyroid function | Changes in Thyroid function test including FT3,FT4,TSH will be assessed. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Secondary | Inflammatory factors | Changes in inflammatory factors includingIL1, IL2, IL6, IL10,TNF ,TGFß and etc. will be assessed. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Secondary | Gut microbiome | Stool samples were collected in time if possible and analyzed the composition /function of the intestinal microflora by High-throughput sequencing | Day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8; 1 month and 3 months post fasting | |
Secondary | Self-rating depression scale; | The Scale ,includes half of items ues positive words and half is negatively,which could assess symptoms of depression. Item responses are ranked from 1 to 4, and higher scores correspond to more frequent symptoms. For each item,patients give a score according to whether the item has occurred: 1 = never/very rarely; 2 = once in a while/some of the time/occasionally; 3 = relatively often/very often/often; 4 = most of the time/always. Each items points accumulated as raw scores,the lowest raw score is 20 points, the highest raw score is 80 points. The raw scores multiply by 1.25, taking the integer part as the standard scores.The scale standard scores were used to define four categories of depression severity: within normal range or no significant psychopathology (below 51points); presence of minimal to mild depression (51-60points); presence of moderate to marked depression (61-70points). | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Secondary | Self-Rating Anxiety Scale; | The Scale contains 20 questions. Each question is scored on a scale of 1-4 (never, some of the time, relatively often, most of the time). There are fifteen questions involved in the assessment could indicate the increase of anxiety levels, and rest of the questions assessment would decrease of the anxiety levels.Each items points accumulated as raw scores,the lowest raw score is 20 points, the highest raw score is 80 points. The raw scores multiply by 1.25, taking the integer part as the standard scores.The scale standard scores were used to define four categories of anxiety severity: within normal ranger no significant psychopathology (25-49points); presence of mild to moderate anxiety levels (50-59points); severe anxiety levels (60-69points); and presence of extreme depression (70-100points). | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Secondary | Hamilton Anxiety Scale | Symptoms of generalized anxiety disorder as measured by the Hamilton Anxiety Scale (HAM-A) at 1 day?4 day?6 day?9 day?40 day. Each item is scored on a scale from 0 (not present) to 4 (severe) with a total score range of 0-56. Changes in HAM-A scores are calculated as the difference between the baseline HAM-A scores and scores at 1 day?4 day?6 day?9 day?40 day. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting | |
Secondary | Hamilton Depression Scale | Remission according to HAM-D: HAM-D17 score less than or equal to (=<) 7 or a HAM-D7 score =< 3. HAM-D17: standardized, clinician-administered rating scale; assesses 17 items characteristically associated with major depression. Individual items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe. Total score: 0 to 66; higher score indicates more depression. HAM-D7: subset of HAM-D17; assesses 7 items associated with major depression. Total score: 0 to 26; higher score indicates more depression. | Day 0, day 3, day 5, day 8; 1 month and 3 months post fasting |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05272332 -
Gastric Ultrasound Prior to Extubation
|
||
Completed |
NCT04247464 -
Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients
|
N/A | |
Completed |
NCT01067001 -
Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study
|
N/A | |
Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
Completed |
NCT01506713 -
Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT04514380 -
Effect of Drinking Carbohydrate-containing Fluids on Gastric Residual Volume in Elderly Patients
|
||
Completed |
NCT05756868 -
The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior
|
N/A | |
Completed |
NCT05134207 -
The Effect of Oral Carbohydrate Solution on Anxiety and Comfort in Patients Undergoing Hip Arthroplasty
|
N/A | |
Completed |
NCT05031598 -
Long-term Fasting: Multi-system Adaptations in Humans
|
N/A | |
Recruiting |
NCT04501393 -
Recommended Clear Fluid Intake Volume at 2 Hours Prior to Esophagogastroduodenoscopy for Adult Patients
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
Completed |
NCT05219136 -
Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol
|
N/A | |
Recruiting |
NCT04625608 -
Effect of Premedicant Oral Paracetamol on Gastric Volume and pH
|
Phase 4 | |
Not yet recruiting |
NCT02562638 -
Pre-Procedural Fasting in Cardiac Intervention
|
N/A | |
Completed |
NCT01954836 -
Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial
|
N/A | |
Completed |
NCT01949987 -
Does Oral Intake Decreases Postoperative Pain Score in Children
|
N/A | |
Completed |
NCT01721187 -
Satiety Effects on the Neural Valuation of Food
|
N/A | |
Completed |
NCT01746719 -
Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition
|
Phase 1 | |
Completed |
NCT01713647 -
Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions
|
Phase 1 | |
Completed |
NCT01831700 -
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions
|
Phase 1 |